$OPCH

Option Care Health, Inc.

Option Care Health provides home and alternate site infusion services to patients with complex and chronic medical conditions across the United States. It contracts with managed care organizations, third-party payers, hospitals, physicians and other referral sources to provide pharmaceuticals, compounded solutions, nursing support, care coordination and clinical monitoring under the direction of patients’ physicians. Its services are delivered in patients’ homes, clinics, physicians’ offices and ambulatory infusion suites. The company operates in one segment, infusion services, with therapies including anti-infectives, nutrition support, immunoglobulin, chronic inflammatory and neurological disorders, bleeding disorders, women’s health and heart failure. Its Naven Health brand provides a nationwide home infusion nursing network and clinical platform. Option Care Health makes most of its money through contracts with third-party payers, including managed care organizations, insurers, employers, Medicare and Medicaid, which reimburse the cost of pharmaceuticals and services. It may also bill patients for amounts not covered by payers and receives fees from certain biotech manufacturers for clinical outcomes and data services. The company is headquartered in Bannockburn, Illinois.

0
0
1
—
$205K
Pate R Carter
0%
See all $OPCH insider activity →
Low

ETFs Are Net Sellers of Option Care Health (OPCH) on Friday

ETFs sold $10.0 million of Option Care Health (OPCH) shares on Friday, extending net selling to three days. DFAT was the largest seller, reducing its stake by 31.5%. OPCH is held by 52 ETFs. The company operates in the healthcare sector, with a market cap of $4.8 billion.

Pate R Carter sold $205K of OPCH

Pate R Carter sold 6,492 shares of Option Care Health, Inc. (OPCH) at $31.65 ($0.21M total) across 2 trades over 2026-11-10 to 2026-11-11.

October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice

FDA accepted uniQure's Huntington disease gene therapy application, with a decision expected in May 2027. AV-1959R (Nuravax) received fast track designation for Alzheimer's prevention. FDA decisions are pending on Bayer's asundexian and Regeneron's cemdisiran. Bristol Myers Squibb reported a patient death in MS trials. Novartis' remibrutinib showed relapse rate reductions in MS trials but no significant disability progression impact.

OPCH sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning OPCH (Option Care Health, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent OPCH coverage spans earnings, financial news and market movers.

In the last 30 days, OPCH insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($205K). The most active reporter was Pate R Carter with 2 filings.

What's driving OPCH

AlphAI scores every news story that mentions OPCH with an AI model for sentiment and relevance, and aggregates insider trades from Option Care Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $OPCH

Score

October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice

FDA accepted uniQure's Huntington disease gene therapy application, with a decision expected in May 2027. AV-1959R (Nuravax) received fast track designation for Alzheimer's prevention. FDA decisions are pending on Bayer's asundexian and Regeneron's cemdisiran. Bristol Myers Squibb reported a patient death in MS trials. Novartis' remibrutinib showed relapse rate reductions in MS trials but no significant disability progression impact.

$OPCH ($OPCH) Releases Q3 2026 Earnings

OPCH reported Q3 2026 earnings of $0.49 per share, missing estimates by $0.00, with revenue of $1.49B, missing estimates by $12.37M. Insider trading and hedge fund activity were noted, with one purchase and significant portfolio changes by institutional investors.

$OPCHHighAI 8/10Earnings

OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2026

Option Care Health, Inc. (OPCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2026 BANNOCKBURN, IL., November 4, 2026 - Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and a

Analyst recommendations: GoDaddy, HubSpot, Microsoft, Palantir

Analysts updated ratings and price targets for several companies. GoDaddy (GDDY) was downgraded by RBC to Sector Perform with a $95 target. Microsoft (MSFT) was downgraded by Phillip Securities to Neutral with a $515 target. T-Mobile (TMUS) was upgraded by Raymond James to Outperform with a $170 target. Other companies affected include HubSpot (HUBS), Palantir (PLTR), and Marathon Petroleum (MPC).

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

Related tickers